Neuroblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The tumor-suppressive miR-186 that is downregulated in neuroblastoma and in TGFβ-treated NK cells represses oncogenic proteins in neuroblastoma (MYCN and AURKA) and components of the TGFβ pathway.
|
30936073 |
2019 |
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Preclinical and early-phase clinical studies of BRD4 and AURKA inhibitors, however, show limited efficacy against neuroblastoma when used alone.
|
30153557 |
2018 |
Neuroblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In line with the prediction of GWL/MASTL enhancing AURKA, elevated expression of GWL/MASTL was associated with NB risk factors and poor survival of patients.
|
26616283 |
2016 |
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.
|
26481147 |
2015 |
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we studied the effects of the pan-aurora kinase inhibitor tozasertib (VX680, MK-0457) and the aurora kinase inhibitor alisertib (MLN8237) that shows some specificity for aurora kinase A over aurora kinase B in a panel of neuroblastoma cell lines with acquired drug resistance.
|
25268132 |
2014 |
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we sought to determine whether inhibition of AURKA modulates neuroblastoma angiogenesis.
|
24439602 |
2014 |
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PTPRD has a tumor suppressor function in neuroblastoma through AURKA dephosphorylation and destabilization and a downstream destabilization of MYCN protein, representing a novel mechanism for the function of PTPRD in neuroblastoma.
|
22305495 |
2012 |
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate AURKA and MYCN gene rearrangements and the chromosomal aberrations (CAs) to determine the prognosis of neuroblastoma.
|
23317189 |
2012 |
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Development of treatment strategies for advanced neuroblastoma.
|
22588779 |
2012 |
Neuroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although it is not yet known if this interaction contributes to neuroblastoma disease pathogenesis, it is intriguing that the interaction occurs at the promoter regions of several genes important for the development of neuroblastoma, including ALK, AURKA and BDNF.
|
21731748 |
2011 |
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In a shRNA screen of genes that are highly expressed in MYCN-amplified tumors, we have identified AURKA as a gene that is required for the growth of MYCN-amplified neuroblastoma cells but largely dispensable for cells lacking amplified MYCN.
|
19111882 |
2009 |
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
STK15 amplification has been previously detected in breast tumour cell lines and in colon tumours; here, we report its amplification in approximately 12% of primary breast tumours, as well as in breast, ovarian, colon, prostate, neuroblastoma and cervical cancer cell lines.
|
9771714 |
1998 |